Laser photocoagulation has changed the long-term outcome of proliferative diabetic retinopathy (PDR) and clinically significant macular edema (CSME).1,2 About 60 to 75% of PDR cases show complete regression of new vessels with pan retinal laser photocoagulation (PRP). 1-3 Successfully regressed PDR cases may require to undergo vitreoretinal surgery for different indications during follow up period. This is because of progressive vitreous contraction. 4-6 The pan metabolic disease of diabetes mellitus (DM) induces changes in vitreous tissue by non-enzymatic glycation of proteins, resembling age-related vitreous degeneration occurring at a much younger age. 7-10 Proliferative diabetic retinopathy further alters the vitreous by inclusion of vasogenic cells and fibrous tissue. 11-14 It is possible that the changes in vitreous due to DM which are independent of retinopathy and the changes in vitreous induced by PDR build indications for vitreoretinal surgery even in laser-treated PDR cases by vitreous contraction such as tractional retinal detachment (TRD), tractional macular edema, secondary rhegmatogenous retinal detachment and recurrent vitreous hemorrhages.4, 15-18 The existing classifications of diabetic retinopathy including the modified Airlie house classification 19-22 do not represent "diabetic vitreopathy" as a clinically identifiable division of the whole pathological complex. This study reviewed a large number of cases and proposed an expanded classification to identify diabetic vitreopathy as a separate class, relatively independent of laser treatment and status of retinopathy. Recently anti vascular endothelial growth factor (anti VEGF) drugs have been used intravitreally to treat difficult PDR cases. 23-26 The proposed classification also identifies the indications for use of these drugs based on our concept of diabetic vitreopathy.
Materials and Methods
A total of 1380 eyes were treated with PRP for the indication of PDR from March 2001 to September 2006.The modified Air lie house classification was followed. Cases included PDR of varying severity such as flat new vessels, with raised new vessels, subhyaloid hemorrhage, vitreous hemorrhage, TRD and macular edema with and without vitreous traction. Thus in some of these cases the clinical evidence of vitreous contraction27 was already present before laser treatment was applied. In order to study the course of changes in the vitreous tissue over long term, we selected 100 eyes photocoagulated for pure PDR without clinically evident vitreous traction (as defined below).
Out of these 100 eyes 74 eyes showing complete regression of new blood vessels following PRP were studied over a follow-up period of one to four years.
Criteria for pure PDR (without clinically evident vitreous traction): selection (1 to 5) and follow-up (6 to 7).
- Proliferative diabetic retinopathy with flat new vessels on the disc (NVD) and /or flat new vessels elsewhere (NVE). 27,28
- Neither hemorrhage in the vitreous nor subhyaloid hemorrhage
- No tractional edema of macula
- No previous ocular surgery
- Absence of systemic hypertension and renal disease
- Fundus fluorescein angiography (FFA) proven regression of new vessels aft er PRP and no recurrence of new vessels during a follow-up of at least one year.
- Presence of other signs of involution in addition to regression of new vessels such as decrease in venous dilatation, disc pallor, disappearance of retinal hemorrhages. 29
Careful history was obtained regarding duration of diabetes, type of diabetes and any other systemic illness (hypertension, renal failure) contributing to retinopathy, concurrent ocular disease and any previous ocular surgery. Cases with such concomitant pathology were not included in the study [Table 1].
Detailed ocular examination including indirect ophthalmoscopy, slit-lamp biomicroscopy, macular examination with three mirror contact lens / 90 D lens and FFA was done. Optical coherence tomography (OCT) was done in 32 eyes with CSME out of 57 eyes (2004 onwards) to rule out vitreous traction. Eyes with any evidence of vitreous traction before PRP were not included in the study.
Pan retinal laser photocoagulation with or without focal /grid macular photocoagulation was done in all the 100 eyes. Green 532 and red 810 diode laser delivered through slit-lamp, were used. Diode laser was preferentially used for macular photocoagulation in the presence of lenticular opacities.30 A mild grey whitening of retina was the end point of treatment with spot size 200 to 300 µ and exposure duration of 0.1 to 0.25 secs, with power level adjusted to produce the desired reaction. Number of burns varied from 2300 to 3700. The PRP was completed in three to four sittings at intervals of four to seven days each; Mainster 165 panfundoscopic lens was used.
Follow-up was available in terms of visual acuity and ocular examination at the first week in all cases. The FFA was done at six weeks (18 cases), eight weeks (64 cases) and 11 weeks (18 cases).
Seventy-four out of 100 eyes responded by way of complete regression of new vessels with laser photocoagulation [Table 2]. Twenty-six eyes required further PRP or other adjunctive treatment. Out of 57 eyes with macular edema visual improvement of two lines or more was observed in 34 eyes, stabilization of visual acuity in 11 eyes and drop of visual acuity by one line or more in 12 eyes. Sixteen out of these 74 eyes required to undergo vitreo retinal surgery within a period of one to four years after complete regression of new vessels following laser photocoagulation [Table 3]. Other signs of regression of PDR such as disc pallor, ghost vessels and reduced venous dilatation were present in only 39 out of 74 cases.
Incidence of PDR was significantly high in Type I DM (P 0.001) and was observed to increase with duration of DM (P 0.001) [Table 1]. Incidence of PDR with and without CSME was significantly high in the age group 41 to 55 years (P 0.05) and also regression of PDR with PRP (P 0.001) [Table 2]. Indications for vitreo retinal surgery were significantly higher in Type I DM (P 0.01), irrespective of age and duration of DM [Table 3].
Diabetes induces pathology throughout the body and also in the vitreous via non-enzymatic glycation of proteins.7,10 Advanced glycosylation end products (AGEs) have been found to be elevated in the vitreous of diabetics along with aggregation of collagen fibers and alterations in the cortex and hyalocytes.8,31 The vitreous in diabetics shows glycated collagen and increased amount of other proteins. 7-9,32 Degenerative vitreous changes occurring in diabetics at a much younger age produce anomalous PVD, which has been said to help formation of new retinal vessels.9,33 Structural changes at the vitreoretinal interface promote migration and proliferation of vasogenic cells in the vitreous, consequent contraction can produce vitreous hemorrhage and macular edema.12,34
Advanced glycation end products correlate with glycemic control and these reactive compounds form on DNA, lipids and proteins where they represent pathophysiological modifications that precipitate dysfunction at a cellular and molecular level in diabetics.10,34
Though the term ″diabetic vitreopathy″ exists in the literature it has not been used to address and identify the pathological complex of diabetic retinopathy in any of the existing classifications of diabetic retinopathy. 19-22 We suggest that changes in the vitreous primarily due to diabetes mellitus and occurring independent of diabetic retinopathy can be called ″primary diabetic vitreopathy″. The methods currently available for examination of the vitreous in vivo including OCT give good information about the vitreo retinal interface but not the vitreous body, therefore such changes in the vitreous may not be easily detected clinically. We may therefore also call ′primary diabetic vitreopathy′ as ′subclinical diabetic vitreopathy′.33
The hallmark of PDR is development of new vessels. The growing vascular endothelium combines with the collagen of the vitreous and gives it a contractile property.2,13,14 Simultaneously fibrous tissue developing along the new vessels lines up on the posterior hyaloid, this also imparts contractile property to the vitreous.11 Contraction of the vitreous can pull new retinal vessels to produce a bleeding in the subhyloid space to begin with [Fig. 1]. If the bleeding is forceful or the vitreous largely liquefied this blood can break into the vitreous tissue concurrently or later. It should be noted here that bleeding outside the tissue confines of retina (internal limiting membrane) is produced by vitreous contraction and not proliferative retinopathy per se and thus any hemorrhage outside the retinal tissue whether subhyloid or in the vitreous should be considered a sign of vitreopathy and not retinopathy. Bleeding further augments the contractile property of the vitreous by inclusion of vasogenic and fibrogenic elements and such recurrent bleeding may result in the formation of fibrovascular tissue in the vitreous cavity. Ongoing contraction of vitreous can result in TRD [Fig. 2], secondary rhegmatogenous retinal detachment, persistent macular edema, premacular hemorrhage in addition to recurrent vitreous hemorrhage.35,36 We propose to call the changes induced in the vitreous tissue by proliferative retinopathy ′secondary diabetic vitreopathy′ or ′clinical diabetic vitreopathy′. These are mainly in the form of an increase in the contractility and detachment of the vitreous. These changes are different from the changes of ′primary diabetic vitreopathy′.
If total vitreous detachment was present before development of PDR no bleeding or tractional retinal detachment may occur. Similarly, if there was no separation of vitreous subsequent to development of retinal new vessels the above pathological events may not occur. There have been several attempts in the past for pharmacological vitreolysis so as to abort any complications of retinal neovascularization by pull of vitreous and there is a continuous suggestion in the literature for early vitrectomy in PDR cases with good vision so as to forestall the complications produced by vitreopathy. 37-39 However, the changes in the vitreous have never been included in any of the classifications of diabetic retinopathy.
Laser ablation of the retina induces regression of new vessels in about two-thirds of cases. 1-3 This results in the disappearance of a ready source of bleeding i.e. new vessels. With laser treatment the incidence of non-resolving massive vitreous hemorrhage has drastically reduced. But the other indications for vitreo retinal surgery such as TRD, rhegmatogenous retinal detachment [Fig. 3], tractional macular edema, premacular fibrosis, small recurrent vitreous hemorrhages, retinal wrinkling, macular heterotropia and dense premacular hemorrhage have persisted. 4-6, 15-18 These are all produced by vitreopathy, vitreous traction and not by PDR alone.
In our series, out of 74 eyes showing complete regression of new vessels with PRP, 16 eyes (23%) required to undergo vitreous surgery for the indications of recurrent vitreous hemorrhage (eight), tractional retinal detachment (four) secondary rhegmatogenous retinal detachment(one) and tractional macular edema (three cases) [Figs.4 A,B,C]. In other words 23% of cases showed a continued contraction of vitreous strong enough to produce the indications for surgery despite successful regression of new vessels. We invited data from leading retina centers in the country on incidence of vitreous surgery in cases of PDR fully regressed with PRP, over a period of one to four years. The reported incidence ranged from 18 to 32%. It is logical to say that in these cases the changes of primary /secondary diabetic vitreopathy were relatively independent of the effect of laser treatment and the regressed status of PDR. In the remaining 77% cases there are several factors which explain the absence of complications produced by diabetic vitreopathy. Regression of new vessels is withdrawal of a ready source of bleeding, multiple chorioretinal adhesions produced by laser protect against TRD and rhegmatogenous retinal detachment. Laser treatment in cases with CSME helps resolution of edema, it is effective in tractional macular edema also if the vitreous traction is not very strong. In addition to the above, PRP induces posterior vitreous detachment in 50% cases and in the large majority this is eventless. A small percentage of these cases may show vitreous bleeding or even TRD during completion of PRP if it is too aggressive and spaced closely.40 We therefore understand that in the large majority of cases (77% in our series) a balance is established between the beneficial effect of laser on retina and the damaging effect of diabetic vitreopathy. In the remaining cases (23% in our series) this balance might not be established and ongoing vitreous contraction might have produced indications for vitreo retinal surgery. Another aspect of the effect of laser photocoagulation is that though the new vessels disappear the fibrous tissue does not and a slow, late cicatrization of fibrous tissue can produce indications like retinal wrinkling, macular heterotropia41 and shallow TRD; we had one such case in our series with retinal wrinkling and TRD occurring in regressed retinopathy after a quiet period of three years [Fig. 5].
We suggest diabetic vitreopathy as a separate subdivision in the existing classification of diabetic retinopathy, identifying the changes induced by diabetes mellitus as ″ primary diabetic vitreopathy″ and the changes induced by PDR as ″secondary diabetic vitreopathy″. It is the changes of secondary diabetic vitreopathy which can be clinically observed and which produce the indications for vitreo retinal surgery, these can be called ″diabetic vitreopathy″ as such or ″clinical diabetic vitreopathy″. We further observe that certain cases of clinical diabetic vitreopathy might not be operable because of extensive neovascularization both in the anterior and posterior segment or many complex fibrovascular membranes in the vitreous. In other words we can have cases which are operable and may benefit by vitreous surgery i.e. ′surgical vitreopathy′ and cases which are inoperable or may not benefit by vitreous surgery i.e. ′non surgical vitreopathy′.
Recently, intravitreal drugs have been used to alter the course of PDR. Two main groups of drugs have been used. First is purified ovine hyaluronidase (Vitrase, ISTA pharmaceuticals) which produces vitreous liquefaction. The second group are anti-VEGF drugs, which reduce neovascularization, contraction of fibrovascular proliferations when PRP is applied and bleeding during surgery. Avastin (Genetech Pharmaceuticals), the commonest drug, has been used as a preoperative adjunct for PDR, TRD with severe PDR, for iris rubeosis, florid disc neovascularization and for treatment of PDR complicated by vitreous hemorrhage. 23-26
This would mean that anti-VEGF drugs can be used in cases which are either inoperable because of extensive neovascularization, massive vitreous hemorrhage or are risky to operate due to the possibility of intraoperative bleeding and other complications. Use of these drugs may render such cases suitable for surgery. In order to identify such cases in a logical manner we suggest a separate class in between surgical and non-surgical vitreopathy as ″intermediate vitreopathy″. The cases put in this class can shift to the surgical vitreopathy group if response to drug is adequate and to the non-surgical vitreopathy group if the drug treatment does not make the case operable.
We suggest the following revised classification for diabetic retinopathy.
The term ″Diabetic Retinopathy″ may be replaced by ″Diabetic Retino-vitreopathy″ and may be classified as below.
Dubey′s classification of diabetic retino-vitreopathy
- Non-proliferative diabetic retinopathy (mild/moderate/ severe/very severe)
- Proliferative diabetic retinopathy
- Diabetic maculopathy (focal, diff use, ischemic, mixed)
- Clinical diabetic vitreopathyi) Surgical vitreopathy
ii) Intermediate vitreopathy
iii) Non-surgical vitreopathy
- Posterior pole TRD 5
- Superior half TRD 16
- Tractional macular edema without macular ischemia 15
- Premacular fibrosis 28
- Recurrent vitreous hemorrhages in laser regressed PDR 4, 17
- Secondary rhegmatogenous retinal detachement 27-28
- Optic disc traction 27, 28
- Macular heterotropia 41
- Retinal wrinkling 41
- Dense premacular hemorrhage 35
- Florid neovascularization with /without any of the above indications 26
- Anterior segment neovascularization 24
- Neovascularization non-responsive to laser with/ without any of the above indications 24-26
- Large non-resolving vitreous bleeding in laser-treated or untreated PDR 26
- Inferior peripheral TRD 16
- Recurrent vitreous hemorrhages in active PDR 28, 36
- Tractional macular edema with ischemia 15, 27
This classification represents all stages and manifestations of diabetic retinopathy including changes in the vitreous. The classification identifies surgical indications and places different manifestations in accordance with the pathology and indicated treatment. For example, tractional diabetic macular edema is classified as surgical vitreopathy as it is the vitreous traction which is the cause and surgery is the treatment.
The classification incorporates the indications for using recent intravitreal anti-VEGF drugs also.
The study sets the direction for further research and investigations on vitreous changes using modern tools such as ultrasound and OCT in diabetics before and after development of diabetic retinopathy and also long-term prospective observations on the retina and vitreous on a larger sample of PDR cases after PRP. Long-term observations following administration of anti-VEGF drugs are indicated.
Diabetic retino vitreopathy is the suggested new nomenclature for diabetic retinopathy. Changes in the vitreous induced by diabetes mellitus are identified as primary diabetic vitreopathy/subclinical diabetic vitreopathy and changes induced by proliferative retinopathy as secondary diabetic vitreopathy/clinical diabetic vitreopathy. Any indications for vitreous surgery in PDR are produced by vitreopathy and not retinopathy per se.
In about two-thirds of PDR cases vitreopathy can be kept under control with adequate PRP, the remaining one-third cases may require surgery due to vitreopathy. A new classification is proposed taking into consideration the element of diabetic vitreopathy as well as the clinical use of intravitreal anti-VEGF drugs.
Dr. Purushott am Dutt a, Gwalior, for discussion and constant encouragement
1. Diabetic Retinopathy Study Research Group. . Photocoagulation treatment of proliferative diabetic retinopathy: Clinical application of diabetic retinopathy study (DRS) findings Ophthalmology. 1981;88:583–600
2. Early treatment of Diabetic Retinopathy Study Research Group. . Photocoagulation for diabetic macular oedema, Early treatment Diabetic Retinopathy Study Arch Ophthalmol. 1995;103:1796–806
3. . Editorial: The diabetic retinopathy study Arch Ophthalmol>. 1973;90:347–8
4. Rogell GD. Late vitreous haemorrhage after successful diabetic pan retinal photocoagulation Presented at American Academy of Ophthalmology Annual Meeting. 1987Dallas, Texas
5. Davis MD. Vitreous contraction in proliferative diabetic retinopathy Arch Ophthalmol. 1965;74:741–51
6. Michels RG. Proliferative diabetic retinopathy: Pathophysiology of extra retinal complications and principles of vitreous surgery Retina. 1981;1:1–17
7. Sebag J, Ansari RR, Dunker S, Suh KI. Dynamic light scattering of diabetic vitreopathy Diabetes Technol Ther. 1999;1:169–76
8. Tomé CC, De Rojas Silva MV, Rodríguez-García J, Rodríguez-Segade S, Sánchez-Salorio M. Levels of pentosidine in vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment Graefes Arch Clin Exp Ophthalmol. 2005;243:1272–6
9. Sebag J. Anomalous posterior vitreous detachment: A unifying concept in vitreo-retinal disease Graefes Arch Clin Exp Ophthalmol. 2004;242:690–8
10. Stitt AW. Advanced glycation: An important pathological event in diabetic and age related ocular disease Br J Ophthalmol. 2001;85:746–53
11. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy Arch Ophthalmol. 1990;108:869–72
12. Faulborn J, Bowald S. Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: Corresponding light and electron microscopic studies Graefes Arch Clin Exp Ophthalmol. 1985;223:130–8
13. Buzney SM, Massicotte SJ. Retinal vessels: Proliferation of endothelium in vitro
Invest Ophthalmol Vis Sci. 1979;18:1191–5
14. Alello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med. 1994;331:1480–7
15. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction Ophthalmology. 1992;99:753–9
16. Charles S, Flinn CE. The natural history of diabetic extra macular tractional retinal detachment Arch Ophthalmol. 1981;99:66–8
17. Diabetic Retinopathy Vitrectomy Study Research Group. . Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: Two-year results of a randomized trial Arch Ophthalmol. 1985;103:1644–52
18. Davis MD. Vitreous contraction in proliferative diabetic retinopathy Arch Ophthalmol. 1965;74:741–51
19. Early Treatment Diabetic Retinopathy Study Research Group. . Grading diabetic retinopathy from stereoscopic color fundus photographs: An extension of the modified Airlie House classification. ETDRS report number 10 Ophthalmology. 19941;98:786–806
20. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales Ophthalmology. 2003;110:1677–82
21. Fukuda M. Clinical arrangement of classification of diabetic retinopathy Tohoku J Exp Med. 1983;141:331–5
22. International clinical classification of diabetic severity of diabetic macular edema: International Council of Ophthalmology October 2002
23. Kuppermann BD, Thomas EL, de Smet MD, Grillone LRVitrase for Vitreous Hemorrhage Study Groups. . Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage Am J Ophthalmol. 2005;140:573–84
24. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (avastin) treatment Retina. 2006;26:352–4
25. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy Retina. 2006;26:699–700
26. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage Retina. 2006;26:275–8
27. Jack J Kanski. Clinical ophthalmology a systematic approach5th Butterworth: Heinemann:447–9
28. Hamilton AM, Dlbig MW, Polkinghorne P. Management of diabetic retinopathy BMJ Publishing Group. 1996:134–40
29. Kanski JJ. Clinical ophthalmology, a systematic approach5th ed Butterworth: Heinemann:447–9
30. Ulbig MW, McHugh DA, Hamilton AM. Diode laser photocoagulation for diabetic macular oedema Br J Ophthalmol. 1995;79:318–21
31. Faulborn J, Dunker S, Bowald S. Diabetic vitreopathy - Findings using the celloidin embedding technique Ophthalmologica. 1998;212:369–76
32. Sebag J. Imaging vitreous Eye. 2002;16:429–39
33. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy Ophthalmology. 1990;97:889–91
34. Stitt AW, Moore JE, Sharkey JA, Murphy G, Simpson DA, Bucala R, et al Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy Invest Ophthalmol Vis Sci. 1998;39:2517–23
35. O′Hanley GP, Lanny CL. Diabetic dense premacular haemorrhage: A possible indication for prompt vitrectomy Ophthalmology. 1985;92:507–11
36. Aaberg TM, Abrams GW. Changing indications and technique for vitrectomy in management of complications of diabetic retinopathy Ophthalmology. 1987;94:775–9
37. Sebag J. Is pharmacologic vitreolysis brewing? Retina. 2002;22:1–3
38. Blackenship GW, Machemer R. Prophylactic vitrectomy in proliferative diabetic retinopathy Mod Probl Ophthalmol. 1977;18:236–41
39. Diabetic retinopathy vitrectomy study research group. . Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: Results of a randomized trial Ophthalmology. 1988;95:1307–20
40. Aylward GW, Pearson RV, Jagger JD, Hamilton AM. Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy Br J Ophthalmol. 1989;73:196–201
41. Bresnick GH, Haight B, de Venecia G. Retinal wrinkling and macular heterotopia in diabetic retinopathy Arch Ophthalmol. 1979;97:1890–5
Source of Support: Nil
Conflict of Interest: None declared